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Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for
many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably
high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This pro-
spective multicenter trial was designed to determine the safety and engraftment efﬁcacy of treosulfan-based
conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related
(n ¼ 4) or unrelated (n ¼ 27) grafts after conditioning with treosulfan (total dose, 42 g/m2), ﬂudarabine (total
dose, 150 mg/m2),  thymoglobulin (6 mg/kg; n ¼ 22). Graft-versus-host disease (GVHD) prophylaxis con-
sisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up
of 2 years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lympho-
histiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to
IV acute GVHD at day 100 and chronic GVHD at 2 years were 62%, 10%, and 21%, respectively. Patients who
received thymoglobulin had a signiﬁcantly lower incidence of grades III to IV acute GVHD (0% versus 33%;
P ¼ .005). These results indicate that the combination of treosulfan, ﬂudarabine, and thymoglobulin is
effective at establishing donor engraftment with low toxicity and improved survival in patients with
nonmalignant diseases and support the need for future disease-speciﬁc clinical trials.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION barrier to engraftment in patients with hemoglobinopathies
The risks for mortality and late effects are the major im-
pediments to using hematopoietic cell transplantation (HCT)
as curative therapy for nonmalignant diseases. In contrast to
aplastic anemia wherein intensive immune suppression
without myeloablation is sufﬁcient to ensure engraftment
[1,2], the marrow space is occupied and forms an additionaledgments on page 2002.
equests: Lauri M. Burroughs, MD, Fred
r, 1100 Fairview Ave North, Suite D5-280,
-1024.
.org (L.M. Burroughs).
14.08.020
lsevier Inc. on behalf of American Society for Bland certain primary immunodeﬁciencies and marrow failure
syndromes. The addition of themyeloablative agent busulfan
to cyclophosphamide and antieT cell serotherapy (anti-
thymocyte globulin [ATG] or Campath) has been successful
in establishing marrow grafts in most of these disorders,
with rejection rates reported to be below 15% for recipients
of HLA-identical sibling marrow grafts [3-7]. However, the
beneﬁt of myeloablative doses of busulfan is largely negated
by potential complications, such as sinusoidal obstructive
syndrome (SOS), the incidence of which depends on the
disease being treated and the partner drugs given in the
regimen [8].ood and Marrow Transplantation.
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monitoring of busulfan levels to guide dose adjustments
[9-11]. In addition, busulfan is associated with late compli-
cations, such as infertility, pulmonary dysfunction, and
deﬁciencies in growth hormone, thyroid hormone, or sex
hormones [12,13]. Many patients with nonmalignant dis-
eases are at high risk for early treatment-related mortality
(TRM) because of infections or organ dysfunction associated
with their underlying disease. To address these problems,
several groups have explored primarily immunosuppressive
nonmyeloablative conditioning regimens, thereby relying on
the graft-versus-host reaction to establish donor engraft-
ment [14-19]. Although the risk for regimen-related toxicity
is low after nonmyeloablative conditioning regimens, there
is a higher risk of mixed chimerism or graft rejection,
particularly among heavily transfused patients. Donor
lymphocyte infusions have been used to increase donor
chimerism but have been associated with greater risk for
graft-versus-host disease (GVHD). Taken together, experi-
ence to date suggests the ideal regimen for achieving
engraftment and minimizing GVHD in patients with
nonmalignant disorders would include a myeloablative
agent that has reduced toxicity.
Treosulfan is a pro-drug of an alkylating agent structurally
related to busulfan; however, treosulfan has a different mode
of alkylation, is not activated by the liver enzymes, and has
highly predictable pharmacokinetics. In preclinical studies,
treosulfan was shown to have antileukemia, myelosup-
pressive, and immunosuppressive properties [20]. Several
European groups studied treosulfan in combination with
ﬂudarabine for conditioning of patients with hematologic
malignancies [21,22]. These studies showed efﬁcacy in
establishing allogeneic hematopoietic stem cell grafts with a
low incidence of regimen-related toxicity. Retrospective an-
alyses by European groups also suggest improved outcomes
among patients with nonmalignant disorders [23]. The
current study was designed as a multicenter, prospective,
open-label trial to evaluate the safety and engraftment efﬁ-
cacy of treosulfan combined with ﬂudarabine as a condi-
tioning regimen for patients with nonmalignant diseases
given an HLA-matched related or unrelated graft.METHODS
Patient eligibility included diagnosis of a nonmalignant disorder other
than acquired aplastic anemia or Fanconi anemia treatable by allogeneic
HCT; age <55 years at time of HCT; adequate organ function, deﬁned as
cardiac ejection fraction 35%, pulmonary DLCO 50%, creatinine 2 times
the upper limit of normal for age, and absence of liver synthetic dysfunction
or severe liver cirrhosis; no evidence for uncontrolled infection or previous
HIV infection; and identiﬁcation of a related or unrelated donor either fully
matched or mismatched for a single allele at HLA-A, -B, -C, -DRB1, or -DQB1.
The protocol was approved by the institutional review boards of all
participating institutions and monitored by an independent Data Safety
Monitoring Board. Patients or their legal guardians provided written
consent.
Theconditioningregimenconsistedof treosulfan14g/m2givenoncedaily
i.v. on days 6 through 4 (total dose, 42 g/m2) and ﬂudarabine 30 mg/m2
givenoncedaily i.v. ondays6through2(totaldose,150mg/m2).Toprevent
GVHD, patients were given tacrolimus and 4 doses of methotrexate as pre-
viouslydescribed [24]. Becauseof ahigher thananticipated incidenceof acute
grades III to IVGVHD in theﬁrst 9patients, thymoglobulin (rabbitATG [rATG])
was added to the regimen and given once daily i.v. on days 4 through 2
(total dose, 6 mg/kg) [25]. Bone marrow was the preferred stem cell source,
infusedonday0;however, unmodiﬁedgranulocyte colony-stimulating factor
mobilized peripheral blood stem cells were allowed if marrow was not
available. Patients were given supportive care, including antibiotic prophy-
laxis, i.v. immunoglobulin, i.v. nutrition, and weekly PCR monitoring for
reactivation of cytomegalovirus, Epstein-Barr virus, and adenovirus, accord-
ing to institutional practices.The pre-HCT comorbidity score was assessed by the HCT comorbidity
index (HCT-CI) [26,27]. Diagnosis, clinical grading, and treatment of acute
and chronic GVHDwere performed according to established criteria [28,29].
Toxicities were deﬁned by the National Cancer Institute’s Common Toxicity
Criteria, version 2.0, excluding hematologic toxicities [30]. Disease response
was evaluated by disease-speciﬁc clinical parameters and cellular functional
assays. Speciﬁcally, in patients with a diagnosis of primary immune deﬁ-
ciency, immune reconstitution was assessed by lymphocyte immuno-
phenotype analysis, lymphocyte proliferation to mitogen and anti-CD3
antibody, and quantitative serum immune globulin production. Additional
immunologic assays included ﬂow cytometry for forkhead box P3 (FOXP3)
in patients with immune dysregulation polyendocrinopathy enteropathy
X-linked syndrome (IPEX), neutrophil oxidative burst in patients with
chronic granulomatous disease (CGD), and natural killer (NK) cell function in
patients with hemophagocytic lymphohistiocytosis (HLH). In patients with
bone marrow failure syndromes, hematopoietic recovery was assessed by
peripheral blood counts and/or bone marrow aspiration or biopsy. Flow
cytometry of peripheral blood for glycosylphosphatidyl inositoleanchored
extracellular proteins was used to assess paroxysmal nocturnal hemoglo-
binuria (PNH), and hemoglobin gel electrophoresis was used to assess sickle
cell disease. Procedures for immunophenotype analyses and sorting of
peripheral blood cell subsets by ﬂow cytometry were described previously
[16]. Donor chimerism levels were assessed in ﬂow cytometry sorted CD33þ,
CD3þ, CD19þ, and CD56þ subsets by PCR-based analyses of polymorphic
microsatellite regions, using methods previously described [31-34].
Study Endpoints and Statistical Analysis
The primary endpoint of the study was engraftment, deﬁned as an
absolute neutrophil count 500 cells/mL for 3 consecutive days with
documented donor CD3þ chimerism. Stopping rules were set for graft failure
>10% or day200 TRM>25%. Donor chimerismwas calculated based on the
percent of CD3þ cells of donor origin and deﬁned as full chimerism if 95%,
high-levelmixed chimerism if50% but<95%, low-level donor chimerism if
5% but <50%, and graft rejection if <5% of donor cells were present. The
main secondary endpoints were TRM at day þ200, acute GVHD grades II to
IV, chronic GVHD, and overall survival. TRM and incidence of GVHD were
calculated using cumulative incidence estimates, treating death due to
disease as a competing risk event for TRM and second HCT, death, and donor
lymphocyte infusions as a competing risk for GVHD. Discontinuation of
systemic immune suppression was calculated using cumulative incidence
estimates, with death on systemic immune suppression as a competing risk
event. Survival curves were calculated using the Kaplan and Meier method.
Cox regression was used to evaluate risk factors for survival. Donor chime-
rism was analyzed with the Wilcoxon rank-sum test.
RESULTS
Patient Characteristics
Between October 24, 2009 and July 3, 2013, 31 consecu-
tive patients meeting eligibility criteria were enrolled. rATG
was added to the regimen for all patients enrolled after June
1, 2011 (n¼ 22). Patient characteristics at the time of HCT are
shown in Table 1. The diagnoses included primary immune
deﬁciency disorders (n ¼ 13; 45%), HLH (n ¼ 6; 19%), bone
marrow failure syndromes (n ¼ 6; 19%), and RBC disorders
(n ¼ 6; 19%). At least 1 comorbidity per the HCT-CI scoring
system was present in 68% of the patients, and 29% had
HCT-CI scores 3. Eighteen patients (58%) had at least 1 of
the following risk factors: HCT-CI  3, failure to thrive, or
previous HCT. Unrelated donor grafts were matched for HLA-
A, -B, -C, -DRB1, and -DQB1 in 26 patients and mismatched
for 1 C allele in 1 patient. Two patients received unrelated
peripheral blood stem cell grafts with cell doses of 20.29 and
11.04  106 CD34þ cells/kg, respectively; all other patients
receivedmarrowgrafts, with amedian cell dose of 5.6 (range,
1.6 to 13.2)  106 CD34þ cells/kg.
Engraftment and Chimerism
Primary engraftment was observed in all patients, with a
median time to neutrophil engraftment of 21 days (range, 12
to 46). Secondary graft failure in the setting of high-level
donor chimerism (75% CD3þ, 100% CD33þ donor cells) was
observed at day þ76 in 1 patient with sickle cell disease. This
Table 1
Patient (N ¼ 31) and Transplant Characteristics
Characteristic Number
Sex (M:F) 22:9
Median age, yr at HCT (range) 10.7 (.4-30.5)
Diagnosis
IPEX 6 (19%)
CGD 5 (16%)
Other PID 2 (10%)
HLH 6 (16%)
DBA 3 (10%)
SDS 3 (10%)
SCD 4 (10%)
PNH 2 (13%)
HCT-CI
0 10 (30%)
1 7 (22%)
2 5 (16%)
3-6 9 (29%)
Failure to thrive 11 (35%)
Previous HCT 3 (10%)
Cell source
MSD marrow 4 (13%)
URD marrow 25 (81%)
URD PBSC 2 (6%)
CMV donor/recipient serology
D/R 12 (39%)
D/Rþ 6 (19%)
Dþ/R 5 (16%)
Dþ/Rþ 8 (26%)
ABO match
Match 12 (39%)
Major mismatch 12 (39%)
Minor mismatch 7 (22%)
PID indicates primary immunodeﬁciency disorder; DBA, Diamond-Blackfan
anemia; SDS, Shwachman-Diamond syndrome; SCD, sickle cell disease;
MSD, matched sibling donor; URD, unrelated donor; PBSC, peripheral blood
stem cells; CMV, cytomegalovirus.
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total nucleated cells/kg. Excluding this patient, the median
time to platelet recovery, deﬁned as >50  109/L for 5 days
without transfusion support, was 23 days (range, 10 to 102).
Donor chimerisms at the most recent evaluation are
shown in Table 2. Among the 9 patients not given rATG,1 had
secondary graft failure (described above) and 2 patients (1
with HLH and 1 with IPEX) had low-level mixed donor
chimerism. Among the 22 patients who received rATG, 19
(86%) had full or high-level mixed donor CD3þ chimerism
and 3 (14%) had low-level mixed donor CD3þ chimerism at
the most recent evaluation. The CD3þ and CD33þ donor
chimerism levels over the ﬁrst year after HCT are shown in
Figure 1. In general, CD3þ donor chimerism remained stable
over time, with no statistically signiﬁcant difference in donor
chimerism levels between patients given rATG and those not
given rATG at any of the assessed time points (day 28, day 84,
6 months, 1 year, P > .25). Two patients received a second
HCT, 1 for treatment of secondary graft failure (described
above) and 1 for treatment of recurrent HLH in the setting of
mixed chimerism (36% CD3þ, 3% CD33þ donor cells). Both
patients had originally received a marrow graft from an HLA-
identical sibling, with CD34þ cell dose/kg of 2.4 and
10.2  106, respectively, and neither had received rATG.
Graft-versus-Host Disease
Grades II to IV acute GVHD occurred in 19 patients for an
overall cumulative incidence of 62%; most were grade II (9
grade IIa, 7 grade IIb). Severe acute GVHD grades III to IV
occurred in 3 patients (10%), none of whom had receivedrATG (Figure 2). The incidence of acute GVHD grades III to IV
was statistically signiﬁcantly reduced in recipients of rATG
(0% versus 33%; P ¼ .005) but was not associated with age or
donor type. Late acute GVHD was observed in 4 patients. The
2-year cumulative incidence of chronic GVHD was 21%
(Figure 2) and was not statistically signiﬁcantly different
between patients who received and did not receive rATG
(P¼ .50). Seventy-eight percent of patients were off systemic
immunosuppression by 2 years after HCT (Figure 2).
Toxicities and Infections
Safety of the regimen was assessed by measurement of
the toxicities observed from the start of conditioning
through day 30 after HCT. In total, 13 patients (42%) devel-
oped 1 or more grade  3 toxicities during this period.
Toxicities commonly associated with myeloablative regi-
mens occurred infrequently; speciﬁcally, grade 3 mucositis
developed in 3 patients (10%) and grade 3 skin rash not
attributable to infection or GVHD occurred in 3 patients
(10%). No patient developed liver toxicity. In addition, 1 pa-
tient developed transient hypoxia (grade 3). Two patients,
ages 5.6 and 23 months, respectively, had a single episode of
a focal seizure that occurred at day þ8 and day þ25,
respectively. In addition, 3 patients developed grade 3
pancreatitis that resolved in all cases. Two patients also
developed a severe allergic reaction to rATG (grade 3),
resulting in its discontinuation after the second dose; both
events resolved. No signiﬁcant toxicities occurred in the 3
patients who had received a prior HCT.
Life-threatening (grade 4) toxicities occurred in 2 patients
(6%), which resolved. One of these patients (who had dia-
phragmatic hemiparesis that preceded transplant) devel-
oped hypoxia and non-infectious pulmonary inﬁltrates on
day 4 and required continuous positive airway pressure
support for 8 days. The other patient who had herpes
stomatitis developed mucosal bleeding and pulmonary in-
ﬁltrates requiring ventilatory support for 17 days. We
observed no apparent difference in toxicity scores according
to patient age or body surface area (BSA).
Within the ﬁrst 100 days after HCT, viral reactivation was
detected by PCR in 11 of 22 patients who received rATG and in
4 of 9 patients not given rATG. All patients with cytomegalo-
virus reactivation (n ¼ 9) received preemptive antiviral
treatment, and no patient developed cytomegalovirus disease.
Reactivation of Epstein-Barr virus was detected in 4 patients,
adenovirus in 2, BK virus in 2, human herpes virus 6 in 2, and
herpes simplex virus in 1. Two patients acquired respiratory
syncytial virus infection on dayþ4, andþ59, respectively, and
were treated successfully with ribavirin. All viral infections
resolved either spontaneously or with antiviral therapies. One
patient with CGD developed a probable pulmonary fungal
infection that resolved after treatment with voriconazole. No
clinically signiﬁcant bacterial infections were observed.
Overall Survival and TRM
Twenty-eight patients survive at a median of 26.1 months
(range, 7 to 48.3) after HCT for a 2-year projected overall
survival of 90% (Figure 3). Day 100 TRMwas 0%. Therewere 3
deaths. One patient died of recurrent central nervous system
(CNS) HLH on day þ233 in the setting of high-level mixed
chimerism (CD33þ 70%, CD3þ 80% donor). One patient with
PNH in complete remission died of GVHD on day þ158; this
patient had not received rATG. One patient with HLH in
complete remission died on day þ129 after a surgical
complication unrelated to HCT.
Table 2
Donor Chimerism and Disease Response According to Diagnosis
Diagnosis Percent Donor Response Follow-
Up (yr)
CD3þ CD33þ
Immune deﬁciency
syndromes
IPEX* 9 0 Normal FOXP3
expression
3.7
IPEX* 100 100 Normal FOXP3
expression
3.0
IPEX 98 100 Normal FOXP3
expression
2.3
IPEX >95 100 Normal FOXP3
expression
2.6
IPEX 100 93 Normal FOXP3
expression
.5
IPEX 37 3 Normal FOXP3
expression
1.6
CGD* 100 100 Normal
neutrophil
oxidative burst
4.0
CGD 100 100 Normal
neutrophil
oxidative burst
2.4
CGD 100 100 Normal
neutrophil
oxidative burst
2.2
CGD 100 100 Normal
neutrophil
oxidative burst
2.0
CGD 90 97 Normal
neutrophil
oxidative burst
2.0
Other PID 100 100 Clinical
remission
of EBV
2.2
Other PID 100 100 Clinical
remission,
off IVIG
2.0
Hemophagocytic
lymphohistiocytosis
HLH* 36 3 Recurrent
disease
1.4y
HLH 80 70 Recurrent
disease
.6z
HLH 100 100 Normal NK
function
2.3
Clinical
remission
HLH 100 100 Normal NK
function
1.7
Clinical
remission
HLH 99 100 Normal NK
function
1.4
Clinical
remission
HLH 100 100 Clinical
remission
.4z
Bone marrow
failure syndromes
DBA 100 100 Normal
hemoglobin,
nontransfused
2.1
DBA 58 68 Normal
hemoglobin,
nontransfused
1.6
DBA 94 100 Normal
hemoglobin,
nontransfused
1.0
SDS* 100 100 Normal blood
count
2.6
Normal bone
marrow
cellularity
(Continued)
Table 2
(continued)
Diagnosis Percent Donor Response Follow-
Up (yr)
CD3þ CD33þ
SDS 100 100 Normal blood
count
2.0
Normal bone
marrow
cellularity
SDS 100 100 Normal blood
count
1.0
Resolution of
cytogenetic
abnormality in
the marrow
RBC disorders
SCD* 75 100 HbS < 5% .3y
SCD* 100 100 HbS < 5% 3.0
Resolution of
symptoms
SCD 100 100 HbS 30% (donor
with HbS trait)
1.4
Resolution of
symptoms
SCD 55 >95 HbS 40% (donor
with HbS trait)
1.0
Resolution of
symptoms
PNH* 100 100 Normal blood
counts
3.4
Normal GPI
expression
PNH* 100 100 Normal blood
counts
.4z
Normal GPI
expression
EBV indicates Epstein-Barr virus; IVIG, intravenous immune globulin; NK,
natural killer cell; HbS, hemoglobin S; GPI, glycosylphosphatidyl inositol.
* No rATG.
y Last evaluation point before a second HCT.
z Died.
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Complete disease responses were observed in 28 patients
(90%; Table 2), as measured by clinical symptoms and lab-
oratory assays. All patients with a diagnosis of a primary
immune deﬁciency disorder or a bone marrow failure
syndrome had complete resolution of disease. Among the 6
patients treated for HLH, 4 achieved complete remissions
and 2 had recurrent disease. Speciﬁcally, 1 patient with a
history of CNS disease pre-HCT experienced CNS relapse at
day þ212 despite high-level mixed donor chimerism and
died of disease, and 1 with low-level mixed chimerism was
given a second HCT for treatment of recurrent HLH and
survives in remission. The 2 patients with PNH experienced
complete disease responses with normalization of blood
counts and normal expression of glycosylphosphatidyl
inositoleanchored extracellular proteins, although 1 died of
GVHD. Among the 4 patients with sickle cell disease, 3
survive without evidence of sickle cell disease and 1 was
given a second HCT for treatment of secondary graft failure
despite high level donor chimerism and hemoglobin S < 5%
and survives without disease.
DISCUSSION
The objective of this study was to establish the safety
and engraftment efﬁcacy of treosulfan and ﬂudarabine
as conditioning for patients with nonmalignant disorders
in a prospective multicenter clinical trial. The results
Figure 1. CD3þ and CD33þ donor chimerism in 31 patients conditioned with
treosulfan and ﬂudarabine. Shown are the percent donor chimerism of sorted
peripheral blood CD3þ (A) and CD33þ (B) subsets according to day after
transplant. The open circles represent percent donor chimerism measured for
patients who were given thymoglobulin (n ¼ 22), and the closed circles
represent percent donor chimerism measured for patients who were not given
thymoglobulin (n ¼ 9) in the regimen. Spline smoothed regression lines reﬂect
the trend in mean chimerism over time, for patients given thymoglobulin
(dashed line) and for patients not given thymoglobulin (solid line). Over-
lapping points at day 28, day 84, day 180, and 1 year and at 100% chimerism,
are jittered slightly to improve visibility.
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abine provides sufﬁcient myeloablation to achieve engraft-
ment in a broad range of nonmalignant disorders without
the potentially serious complications associated with tradi-
tional myeloablative regimens such as busulfan and cyclo-
phosphamide. Speciﬁcally, there were no deaths within the
ﬁrst 100 days, and no patient developed SOS, multiorgan
failure, or fatal infections. Of the 3 deaths, 1 was caused by
GVHD in a patient who did not receive rATG and was
considered transplant related. The other causes of death
included recurrent CNS HLH and a surgical complication
unrelated to HCT. Grade 4 toxicities were limited, and the low
incidence of regimen-related mortality compared with his-
toric results observed with busulfan and cyclophosphamide-
based regimens was quite encouraging, especially because
more than 50% of the patients in this study had risk factors
for poor outcome. For high-risk patients in particular, a less
toxic yet sufﬁciently myeloablative HCT regimen such as
treosulfan and ﬂudarabine may provide considerable beneﬁt
and perhaps will encourage HCT earlier in the disease course
before the development of signiﬁcant comorbidities.
The incidence of viral reactivation did not appear to be
higher in the rATG cohort, although the small number of
patients in the comparator group limits the interpretation of
this observation. Importantly, no patient died from infectiouscomplications. The use of rATG correlated with a lower
incidence of severe acute GVHD. The relatively high inci-
dence of grades II to IV acute GVHD reported here may be
explained in part by the predominance of unrelated donor
grafts in this study and by an increase in diagnostic sensi-
tivity for GVHD of the upper intestinal tract, reﬂecting the
early use of endoscopic biopsies to detect GVHD in patients
with anorexia, as previously described [35].
The combination of treosulfan and ﬂudarabine was ﬁrst
reported by Casper et al. [36] as a reduced-toxicity regimen
for adult patients with hematologic malignancies who were
ineligible for standard myeloablative regimens because of
comorbidities. In this and subsequent studies of patients
with hematologic malignancies, treosulfan was dosed at 30
to 42 g/m2, resulting in a very low incidence of regimen-
related mortality, SOS, and multiorgan failure, with
engraftment rates exceeding 90% [21,22,37-39]. The most
common toxicities associated with treosulfanwere skin rash,
mild mucositis, and transient elevation of hepatic
transaminases.
The few reported studies of treosulfan-based condition-
ing in pediatric patients have been retrospective analyses.
Greystoke et al. [23] reported outcomes for 32 children with
nonmalignant diseases who received treosulfan (36 to 42 g/
m2) alone or in combination with antieT cell serotherapy,
ﬂudarabine, or cyclophosphamide. Graft sources included
HLA-matched or -mismatched related or unrelated marrow
or peripheral blood or HLA-mismatched unrelated umbilical
cord blood. Skin toxicity was reported for 46% of patients,
whereas fatal SOS was observed only once, and the overall
survival was 84%. Slatter et al. [40] reported similar results
for 70 patients with nonmalignant disorders given treo-
sulfan, 36 to 42 g/m2, combined with ﬂudarabine or cyclo-
phosphamide with or without antieT cell serotherapy
conditioning for HLA-matched or -mismatched grafts. Over-
all survival was 81%, and deaths were mainly from late
complications of HCT. Seizures were noted in 4 infants. More
recently, Beier et al. [41] reported the outcomes of 109 pe-
diatric patients with hematologic malignancies or nonma-
lignant disorders. Patients were conditioned with treosulfan
(21 to 42 g/m2) combined with various agents, including
ﬂudarabine, cyclophosphamide, thiotepa, melphalan, total
body irradiation, or antieT cell serotherapy, followed by
HLA-matched or -mismatched marrow or cord blood grafts.
Similarly, low incidences of toxicities were reported,
including SOS in 3%, high-grade skin toxicity in 4%, and sei-
zures in 4% of patients. Taken together, these retrospective
studies suggest that treosulfan-based regimens were asso-
ciated with less toxicity compared with historic rates asso-
ciated with busulfan-based regimens, and we have now
substantiated these ﬁndings in a prospective multicenter
study.
It may be argued that a prospective study of reduced-
toxicity conditioning in a diverse group of patients will
make it difﬁcult to draw conclusions regarding its usefulness
in speciﬁc disorders. However, each of these disorders is rare,
and analysis of safety and efﬁcacy would be protracted if
such studies were limited to only a single disorder. Our
results establish the overall safety of the treosulfan and
ﬂudarabine regimen and suggest that this regimen will be
effective for establishing allografts in multiple disorders.
Speciﬁcally, all patients with immune deﬁciency disorders,
including IPEX and CGD, are surviving with disease resolu-
tion, as are all patients with bone marrow failure synd-
romes (Shwachman-Diamond syndrome, Diamond-Blackfan
Figure 2. Acute and chronic GVHD. Shown is the cumulative incidence of acute GVHD grades II to IV (A) and acute GVHD grades III to IV (B) according to whether
patients were given thymoglobulin (dashed line, n ¼ 22) or not given thymoglobulin (solid line, n ¼ 9) in the regimen. (C) Cumulative incidence of chronic GVHD. (D)
Cumulative incidence of discontinuation of systemic immune suppression (Off ISS) after HCT.
L.M. Burroughs et al. / Biol Blood Marrow Transplant 20 (2014) 1996e2003 2001anemia). Our results may also suggest that some disorders
may be more resistant to engraftment with this regimen,
because 2 of 6 patients with HLH experienced relapsed
disease in the setting of mixed chimerism, 1 of whom
required a second HCT and 1 of 4 patients with sickle cell
disease required a second HCT for correction of secondary
graft failure. Although these numbers are too small to draw
ﬁrm conclusions, several studies support the feasibility of
intensifying the regimen without excessive toxicity through
the addition of thiotepa, particularly in patients with
thalassemia major and HLH [42-45].
The more predictable pharmacokinetics of treosulfan
offers the advantage of dispensing with drug-level deter-
mination required for targeting busulfan. However, thereFigure 3. Overall survival, disease-free survival, and TRM (n ¼ 31). Shown are
the Kaplan-Meir estimates of overall survival (solid line) and disease-free
survival (dashed line) and the cumulative incidence of TRM (dotted line).remains a question about the appropriate dosing of
treosulfan in very young patients, particularly infants.
Glowka et al. [46] reported results of treosulfan pharmaco-
kinetic studies in 7 patients ages 2 to 15 years, 5 of whom
received 3 doses of treosulfan at 12 g/m2 per day and 1 each
who received doses of 10 g/m2 or 14 g/m2. The median area
under the curve for those given the 12 g/m2 dose was similar
to that reported for adults [46]. More recently, ten Brink et al.
[47] used a limited sampling strategy to estimate treosulfan
pharmacokinetics in 20 children (median age, 6.2 years)
given 14 g/m2 treosulfan. Results showed predictable
pharmacokinetics of treosulfan and limited interpatient
variability. No correlation with outcome was provided in
either report. Based on these studies, as well as on unpub-
lished data in 7 children who weighed <10 kg, a preliminary
population pharmacokinetic model was developed and dose
recommendations on individual BSA were derived. The
current dose recommendations are to use 14 g/m2/day
treosulfan for patients with a BSA >1.0 m2, 12 g/m2/day for a
BSA > .5 to 1.0 m2, and 10 g/m2/day for those with
BSA  .5 m2. Results of our study suggest this dose adjust-
ment may not be necessary, because all patients were given
doses of 14 g/m2 regardless of age or BSA. We observed no
apparent difference in toxicity scores or mortality according
to patient age or BSA. Therefore, it is not clear that dose
adaptation would offer any beneﬁt in smaller children and
could potentially lower the myeloablative effect of treo-
sulfan, leading to a higher incidence of graft rejection.
Further prospective studies are warranted to better
understand the dose effect of treosulfan in patients with
nonmalignant diseases and for patients with alternative
donor grafts such as umbilical cord blood. Patients in this
study should be monitored for the potential late effects and
the long-term stability of engraftment after treosulfan-based
conditioning. The results of this multicenter prospective
L.M. Burroughs et al. / Biol Blood Marrow Transplant 20 (2014) 1996e20032002study support the use of treosulfan, ﬂudarabine, and rATG
conditioning for patients with nonmalignant disorders as a
means to achieve engraftment of HLA-matched grafts with
minimal risk for mortality or morbidity.ACKNOWLEDGMENTS
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